Metabolomics in Pathogenic Pathways and Targeted Therapies for Diabetic Neuropathy: A Comprehensive Review
Introduction and objective: This literature review aims to provide an overview of the progress in metabolomic assessment in animal and cell models and in humans with diabetic neuropathy (DN). Methods: Metabolomics has emerged as an important approach for investigating, identifying, and describing bi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/15/2/86 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849719778365669376 |
|---|---|
| author | Cornelia Bala Adriana Rusu Dana Mihaela Ciobanu Gabriela Roman Anca Elena Crăciun |
| author_facet | Cornelia Bala Adriana Rusu Dana Mihaela Ciobanu Gabriela Roman Anca Elena Crăciun |
| author_sort | Cornelia Bala |
| collection | DOAJ |
| description | Introduction and objective: This literature review aims to provide an overview of the progress in metabolomic assessment in animal and cell models and in humans with diabetic neuropathy (DN). Methods: Metabolomics has emerged as an important approach for investigating, identifying, and describing biomarkers related to DN. None has yet been validated for use in clinical practice. Results: DN induced significant alterations in energy metabolism and carbohydrates, lipids, amino acids, peptides, and proteins. Several treatments for DN, evaluated using metabolomics, were proved to have promising results. Conclusions: The ideal metabolite or set of metabolites that could be used as biomarkers should identify patients with diabetes prone to develop DN or those prone to progress to severe forms of sensory loss, associated with risk of ulcerations and amputation. Another potential use of a metabolite might be as an indicator of treatment response in clinical trials using agents with potential disease-modifying properties. |
| format | Article |
| id | doaj-art-5ae8a8a2c3cc4311adf74a1ee92abdb3 |
| institution | DOAJ |
| issn | 2218-1989 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj-art-5ae8a8a2c3cc4311adf74a1ee92abdb32025-08-20T03:12:05ZengMDPI AGMetabolites2218-19892025-02-011528610.3390/metabo15020086Metabolomics in Pathogenic Pathways and Targeted Therapies for Diabetic Neuropathy: A Comprehensive ReviewCornelia Bala0Adriana Rusu1Dana Mihaela Ciobanu2Gabriela Roman3Anca Elena Crăciun4Department of Diabetes and Nutrition Diseases, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, RomaniaDepartment of Diabetes and Nutrition Diseases, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, RomaniaDepartment of Diabetes and Nutrition Diseases, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, RomaniaDepartment of Diabetes and Nutrition Diseases, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, RomaniaDepartment of Diabetes and Nutrition Diseases, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, RomaniaIntroduction and objective: This literature review aims to provide an overview of the progress in metabolomic assessment in animal and cell models and in humans with diabetic neuropathy (DN). Methods: Metabolomics has emerged as an important approach for investigating, identifying, and describing biomarkers related to DN. None has yet been validated for use in clinical practice. Results: DN induced significant alterations in energy metabolism and carbohydrates, lipids, amino acids, peptides, and proteins. Several treatments for DN, evaluated using metabolomics, were proved to have promising results. Conclusions: The ideal metabolite or set of metabolites that could be used as biomarkers should identify patients with diabetes prone to develop DN or those prone to progress to severe forms of sensory loss, associated with risk of ulcerations and amputation. Another potential use of a metabolite might be as an indicator of treatment response in clinical trials using agents with potential disease-modifying properties.https://www.mdpi.com/2218-1989/15/2/86metabolomicsdiabetes mellitusdiabetic neuropathies |
| spellingShingle | Cornelia Bala Adriana Rusu Dana Mihaela Ciobanu Gabriela Roman Anca Elena Crăciun Metabolomics in Pathogenic Pathways and Targeted Therapies for Diabetic Neuropathy: A Comprehensive Review Metabolites metabolomics diabetes mellitus diabetic neuropathies |
| title | Metabolomics in Pathogenic Pathways and Targeted Therapies for Diabetic Neuropathy: A Comprehensive Review |
| title_full | Metabolomics in Pathogenic Pathways and Targeted Therapies for Diabetic Neuropathy: A Comprehensive Review |
| title_fullStr | Metabolomics in Pathogenic Pathways and Targeted Therapies for Diabetic Neuropathy: A Comprehensive Review |
| title_full_unstemmed | Metabolomics in Pathogenic Pathways and Targeted Therapies for Diabetic Neuropathy: A Comprehensive Review |
| title_short | Metabolomics in Pathogenic Pathways and Targeted Therapies for Diabetic Neuropathy: A Comprehensive Review |
| title_sort | metabolomics in pathogenic pathways and targeted therapies for diabetic neuropathy a comprehensive review |
| topic | metabolomics diabetes mellitus diabetic neuropathies |
| url | https://www.mdpi.com/2218-1989/15/2/86 |
| work_keys_str_mv | AT corneliabala metabolomicsinpathogenicpathwaysandtargetedtherapiesfordiabeticneuropathyacomprehensivereview AT adrianarusu metabolomicsinpathogenicpathwaysandtargetedtherapiesfordiabeticneuropathyacomprehensivereview AT danamihaelaciobanu metabolomicsinpathogenicpathwaysandtargetedtherapiesfordiabeticneuropathyacomprehensivereview AT gabrielaroman metabolomicsinpathogenicpathwaysandtargetedtherapiesfordiabeticneuropathyacomprehensivereview AT ancaelenacraciun metabolomicsinpathogenicpathwaysandtargetedtherapiesfordiabeticneuropathyacomprehensivereview |